ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome
| Status: | Archived |
|---|---|
| Conditions: | Cancer, Blood Cancer |
| Therapuetic Areas: | Oncology |
| Healthy: | No |
| Age Range: | Any |
| Updated: | 7/1/2011 |
| Start Date: | June 2009 |
A Phase 1 Study of Oral ARRY-614 in Patients With Low or Intermediate-1 Risk Myelodysplastic Syndrome
This is a dose-escalation study to determine the maximum tolerated dose (MTD) of ARRY-614 in
patients with Myelodysplastic Syndrome (MDS).
We found this trial at
3
sites
M. D. Anderson Cancer Center Welcome to UF Health Cancer Center at Orlando Health. For...
Click here to add this to my saved trials
12902 USF Magnolia Dr
Tampa, Florida 33612
Tampa, Florida 33612
(888) 663-3488
H. Lee Moffitt Cancer Center & Research Institute Moffitt Cancer Center in Tampa, Florida, has...
Click here to add this to my saved trials
Click here to add this to my saved trials